Trimetazidine dihydrochloride is an anti-ischemic metabolic agent classified as a piperazine derivative that treats angina pectoris by inhibiting long-chain fatty acid oxidation to improve myocardial oxygen… Read more
Trimetazidine dihydrochloride is an anti-ischemic metabolic agent classified as a piperazine derivative that treats angina pectoris by inhibiting long-chain fatty acid oxidation to improve myocardial oxygen utilization. This category includes high-quality reference standards for the active pharmaceutical ingredient, alongside its related pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. Pharmaceutical laboratories rely on these specialized materials for rigorous impurity profiling, method validation, and ongoing quality control during the manufacturing process. By providing consistent and reliable standards, these compounds assist in identifying degradation products and verifying the stability of the drug, ensuring that regulatory standards for purity and compliance are met throughout the analytical lifecycle.
